A multi-national phase III study of satraplatin plus prednisone or placebo plus prednisone in patients with hormone refractory prostate cancer previously treated with one cytotoxic chemotherapy regimen.
Phase of Trial: Phase III
Latest Information Update: 09 Sep 2016
At a glance
- Drugs Prednisone (Primary) ; Satraplatin (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms SPARC
- Sponsors Agennix AG
- 30 Apr 2012 Company (Agennix AG) added as reported by ClinicalTrials.gov.
- 05 Oct 2009 Results published in the Journal of Clinical Oncology.
- 09 Mar 2009 Results of a subgroup analyses regarding a secondary endpoint were presented at the 2009 Genitourinary Cancers Symposium.